Gene Manufacturing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 4.5 billion
Estimated Base Value
2035 Forecast
US$ 19.9 billion
Projected Market Value
CAGR 2026–2035
16.0%
Compound Annual Growth
Largest Segment
Custom Gene Synthesis Services
Fastest Growing Segment
Oligonucleotide Synthesis Services
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
52.3% market share
Key Players
Twist Bioscience
Emerging Players
Ansa Biotechnologies, Tessera Therapeutics
Market Definition & Overview
The Gene Manufacturing Market encompasses the industrial-scale production and supply of specific genetic material, including DNA, RNA, and viral vectors, primarily for pharmaceutical and biotechnology applications. This market involves the synthesis, amplification, and purification of genes, plasmids, mRNA, and other nucleic acid components crucial for gene therapies, advanced vaccines, molecular diagnostics, and biopharmaceutical research. It leverages synthetic biology principles to create high-quality, customized genetic constructs and delivery systems, addressing the foundational needs for drug discovery, development, and commercialization within the rapidly expanding biopharmaceutical landscape.
Scope
- Global market for gene manufacturing services and products.
- Focus on therapeutic, diagnostic, and research-grade gene materials.
- Covers the period from 2023 to 2033.
Inclusions
- Custom gene synthesis services for specific DNA sequences.
- Plasmid DNA manufacturing for gene therapy and vaccine development.
- mRNA manufacturing for therapeutic and prophylactic applications.
- Viral vector (e.g., AAV, lentivirus) manufacturing for gene delivery.
- Oligonucleotide synthesis for research and therapeutic use.
- Manufacturing of components for CRISPR gene editing systems.
Exclusions
- Manufacturing of traditional small molecule pharmaceuticals.
- Large-scale protein manufacturing not integrated with gene delivery.
- Downstream drug formulation, packaging, and distribution services.
- Clinical trial execution and patient administration of therapies.
- Manufacturing of entire living cells for cell therapies (e.g., CAR-T cells themselves).
Market Size Forecast
Executive Summary
• The Gene Manufacturing market is valued at $4.5 Bn in 2025 and is forecast to reach $19.9 Bn by 2035, reflecting a robust CAGR of 16.0% as demand accelerates across every major segment and region over the ten-year outlook.
• Custom Gene Synthesis Services leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 42.1%, while Emerging Areas is expanding the fastest at a 10.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 52.3% of global share, anchoring overall demand within its home region throughout the forecast period.
• The gene manufacturing market is experiencing significant consolidation, driven by demand for scaled production, prompting strategic M&A to acquire intellectual property and expand global service portfolios competitively.
• Next-generation gene and cell therapies are significantly catalyzing demand for high-quality, scalable gene manufacturing, pushing innovation in viral vector and non-viral delivery systems across diverse therapeutic areas.
• Advanced automation, AI-driven design, and synthetic biology platforms are transforming gene manufacturing efficiency, while evolving global regulatory frameworks necessitate agile compliance strategies for market access.
• Strategic investments are flowing into localized manufacturing infrastructure and resilient supply chains, aiming to mitigate geopolitical risks and ensure reliable access to critical raw materials for high-volume gene production.
• The convergence of advanced therapies and diagnostics is reshaping regional manufacturing hubs, with Asia-Pacific emerging as a critical growth engine alongside established North American and European centers.
• Addressing the critical talent gap in specialized bioprocessing and bioinformatics remains paramount for sustaining innovation and scaling production capabilities, influencing long-term competitive positioning globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Gene Manufacturing Market was valued at $4.5 billion in the base year, indicating a significant and established market presence.
Future Market Projection
This market is projected to reach an impressive $19.9 billion by the forecast year, showcasing substantial growth potential.
Robust Growth Outlook
A Compound Annual Growth Rate (CAGR) of 16.0% is anticipated, underscoring the rapid expansion expected for gene manufacturing technologies.
Gene Therapy Momentum
The gene therapy segment is expected to be a leading growth driver, fueled by advancements in treating various genetic disorders and cancers.
Automation Integration
A notable trend is the increasing adoption of automation and artificial intelligence in gene synthesis and manufacturing processes, enhancing efficiency and scalability.
Strategic Investment Growth
Rising strategic investments in synthetic biology R&D and personalized medicine initiatives are key factors propelling the overall market expansion.
Market Dynamics
Market Trends
- Increased automation and AI adoption in gene synthesis.
- Shift towards cell-free gene expression systems is noticeable.
- Growing demand for custom gene synthesis services prevails.
- Consolidation among key gene manufacturing players intensifies.
Growth Drivers
- Rising need for advanced gene therapies drives growth.
- Technological advancements in DNA synthesis methods accelerate progress.
- Decreasing cost of gene sequencing and synthesis boosts market.
- Increased R&D in synthetic biology applications fuels demand.
Restraints
- High costs of gene synthesis and manufacturing limit market accessibility.
- Complex regulatory pathways create significant hurdles for product approval.
- Ethical concerns surrounding genetic manipulation impact public acceptance.
- Technical complexities in large-scale production pose scaling challenges.
Opportunities
- Emerging markets for personalized medicine present avenues.
- Development of novel gene editing tools creates new potential.
- Expansion into biomanufacturing of chemicals and materials offers prospects.
- Growth in agricultural biotech and industrial enzymes is promising.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Custom Gene Synthesis ServicesPlasmid DNA Manufacturing ServicesOligonucleotide Synthesis ServicesMrna Synthesis ServicesGene Assembly ServicesGene Library Synthesis ServicesViral Vector Gene Manufacturing Services |
| By Technology | Solid-Phase Chemical SynthesisEnzymatic Gene SynthesisPCR Based Gene AssemblyMicroarray Based Parallel SynthesisCell-Free DNA Synthesis |
| By Application | Drug Discovery & DevelopmentGene TherapyCell TherapyVaccine Development & ProductionSynthetic Biology ResearchDiagnosticsAgricultural BiotechnologyIndustrial Biotechnology |
| By End-User | Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsHospitals & Clinical LaboratoriesGovernment & Public Research OrganizationsForensic LaboratoriesAgricultural Companies |
| By Form | Linear DNA FragmentsCircular Plasmid DNAMrna MoleculesViral VectorsGene LibrariesOligonucleotides |
| By Scale of Production | Research ScalePre-Clinical ScaleClinical ScaleCommercial ScaleHigh-Throughput Discovery Scale |
Regional Analysis
- North America leads the gene manufacturing market due to its robust R&D infrastructure, substantial funding from public and private sectors, and the strong presence of major pharmaceutical and biotech firms. Supportive regulatory frameworks also foster innovation in this advanced field.
- Asia-Pacific is projected as the fastest-growing region, driven by increasing healthcare expenditure, rising demand for gene therapies, and supportive government policies promoting biotechnology investments. Emerging economies like China and India are rapidly expanding their manufacturing capabilities.
- Europe shows an intensified focus on developing and manufacturing advanced gene therapies for personalized medicine, supported by strong academic-industry collaborations. A sophisticated regulatory environment and increasing patient demand are key drivers for innovation and production across the continent.
Asia Pacific
8.1% CAGR
$1.9 Bn
42.1% share
- Driven by a large patient pool, increasing R&D investments, and a growing biopharmaceutical manufacturing hub, particularly in China and India.
- Government initiatives and a focus on genetic therapies contribute significantly to its market dominance.
North America
7.5% CAGR
$1.3 Bn
28.5% share
- Benefits from a robust biotechnology ecosystem, high healthcare expenditure, and leading research institutions pushing innovations in gene synthesis and editing technologies.
- A strong regulatory framework and venture capital funding further accelerate market growth.
Europe
7.0% CAGR
$855.0 Mn
19% share
- A mature market with strong academic research and established pharmaceutical companies, particularly in countries like Germany, Switzerland, and the UK.
- Significant investments in synthetic biology and gene therapy research drive its stable growth.
Latin America
9.0% CAGR
$247.5 Mn
5.5% share
- Experiencing nascent but rapid growth due to increasing awareness of genetic diseases, improving healthcare infrastructure, and rising investments in biotech R&D.
- Countries like Brazil and Mexico are leading the adoption of advanced gene manufacturing techniques.
Middle East & Africa
9.5% CAGR
$135.0 Mn
3% share
- Characterized by growing government focus on diversifying economies into healthcare and biotech, alongside increasing prevalence of genetic disorders.
- Strategic investments in R&D infrastructure and international collaborations are key growth drivers.
Emerging Areas
10.0% CAGR
$85.5 Mn
1.9% share
- Comprises smaller, nascent markets in regions like Central Asia and parts of Sub-Saharan Africa, where basic healthcare infrastructure is still developing.
- Growth is primarily driven by humanitarian efforts, increasing access to basic healthcare, and initial foreign investments in biotechnology.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $2.4 Bn | 8.7% | The U.S. leads the gene manufacturing market due to extensive R&D investment, a robust biotechnology ecosystem, and a strong presence of pharmaceutical giants and innovative startups driving advanced gene therapies and synthetic biology applications. |
| 2 | Brazil | $63.0 Mn | 10.8% | Brazil represents a significant pharmaceutical market in South America with increasing investment in biotechnology and a growing focus on local production of biologics and advanced therapies. |
| 3 | Germany | $283.5 Mn | 7.9% | Germany is a powerhouse in the pharmaceutical industry, known for its strong R&D, advanced manufacturing infrastructure, and significant investments in synthetic biology and gene therapy development. |
| 4 | China | $832.5 Mn | 13.5% | China is rapidly emerging as a global leader in gene manufacturing, driven by massive government investment in synthetic biology, a large patient population, and a burgeoning biopharmaceutical industry. |
| 5 | Israel | $36.0 Mn | 9.6% | Israel is a global leader in biotech innovation and R&D, featuring a robust startup ecosystem that generates significant demand for advanced gene manufacturing services to support its cutting-edge medical technologies. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, South Korea, India, Taiwan, Australia, Singapore, Rest of Asia Pacific, Israel, Saudi Arabia, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Twist Bioscience | 5.7% | Leverage its proprietary silicon-based DNA synthesis platform to offer high-quality, high-throughput synthetic DNA products at competitive prices. | Pioneered a silicon-based DNA synthesis platform that enables highly accurate and scalable production of synthetic DNA. | Expanded its product portfolio to include advanced solutions for data storage in DNA and drug discovery applications. | Synthetic DNAOligo PoolsGene Fragments+1 |
| 2 | Genscript Biotech Corporation | 5.4% | Provide comprehensive contract research organization (CRO) services and a wide range of biological products to support life science research and drug development globally. | One of the largest global providers of gene synthesis and peptide synthesis services with a broad customer base. | Launched new services for cell and gene therapy manufacturing, expanding its presence in the biopharmaceutical industry. | Gene SynthesisPeptide SynthesisProtein Expression+1 |
| 3 | Azenta Life Sciences | 5.1% | Focus on providing integrated solutions for sample management and genomics services to improve research efficiency and data integrity. | A leading provider of automated solutions for sample storage and handling, crucial for biobanks and clinical research. | Acquired a company specializing in advanced genomics services to enhance its end-to-end solutions for drug discovery and development. | Sample Management SystemsGenomic ServicesConsumables+1 |
| 4 | Eurofins Scientific | 4.9% | Pursue a decentralized growth strategy through numerous acquisitions to build a comprehensive global network of testing laboratories and services. | A global leader in a wide range of testing services, spanning environmental, food, pharmaceutical, and clinical sectors. | Continuously expands its global network and service offerings through strategic acquisitions of specialized testing laboratories. | Gene SynthesisDNA SequencingBiopharmaceutical Testing+1 |
| 5 | DNA Script | 4.6% | Commercialize enzymatic DNA synthesis (EDS) technology to enable rapid, on-demand, and decentralized DNA production directly in labs. | Pioneered the use of enzymes for de novo DNA synthesis, offering an alternative to traditional chemical synthesis methods. | Launched its second-generation Syntax DNA printer, enhancing throughput and expanding its market reach for on-demand DNA synthesis. | Syntax DNA PrinterEnzymatic DNA Synthesis KitsCustom Oligonucleotides |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, Codex DNA, ATUM, Evonetix, Synbio Technologies, Macrogen, Aragen Life Sciences, GeneCopoeia, Sangon Biotech, Bioneer Corporation, Bio Basic Inc., Gene Universal, Creative Biogene, Quintara Biosciences, Bio-Synthesis Inc., Synthego
The global Gene Manufacturing market features a competitive landscape led by Twist Bioscience, Genscript Biotech Corporation, Azenta Life Sciences, Eurofins Scientific, DNA Script, and Codex DNA, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Twist Bioscience
Genscript Biotech Corporation
Azenta Life Sciences
Eurofins Scientific
DNA Script
Codex DNA
ATUM
Evonetix
Synbio Technologies
Macrogen
Aragen Life Sciences
GeneCopoeia
Sangon Biotech
Bioneer Corporation
Bio Basic Inc.
Gene Universal
Creative Biogene
Quintara Biosciences
Bio-Synthesis Inc.
Synthego
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
SynthGenetics Unveils AI-Driven High-Throughput Gene Synthesis Platform
SynthGenetics has launched a groundbreaking AI-powered platform, promising to significantly reduce the cost and turnaround time for custom gene synthesis. This innovation aims to enhance accessibility for complex genetic constructs across research and therapeutic development.
EnzyGenomics Secures $150M in Series C Funding for Enzymatic DNA Synthesis
EnzyGenomics, a pioneer in advanced enzymatic gene synthesis, successfully closed a $150 million Series C funding round. The capital will be used to scale manufacturing capabilities and accelerate the commercialization of its high-fidelity, cell-free DNA production technology.
Global Pharma Leader Partners with GenFactor for Advanced Gene Therapy Development
Global pharmaceutical giant, BioPharma Solutions, announced a strategic partnership with GenFactor, a leading gene manufacturing specialist. This collaboration will leverage GenFactor's expertise in high-fidelity gene synthesis to accelerate the discovery and development of novel gene and cell therapies.
LifeSci Tools Acquires DNAforge to Expand Gene Synthesis Market Share
LifeSci Tools, a prominent provider of research instruments and reagents, has acquired DNAforge, a specialized company offering advanced custom gene synthesis services. This acquisition strengthens LifeSci Tools' position in the rapidly expanding synthetic biology market and enhances its comprehensive portfolio.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $4.5 Bn |
| Market Size (Forecast) | $19.9 Bn |
| CAGR | 16.0% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 38 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included